Taxifolin (Flavanonol)

Taxifolin is a flavanonol compound found in milk thistle and larch trees that functions as a potent antioxidant and anti-inflammatory agent. This bioactive flavonoid crosses the blood-brain barrier and may help reduce amyloid-beta protein accumulation associated with cognitive decline.

Origin & History

Taxifolin is a flavanonol, a subclass of flavonoids within the polyphenol family, naturally occurring in various plants including pine needles from Larix species, cedar, other conifers, as well as fruits like apples and grapes. Commercial extraction typically involves solvent extraction from plant sources such as larch wood or pine bark, followed by purification to isolate the compound.

Historical & Cultural Context

No information on traditional or historical medicinal uses of taxifolin is available in the current research. The compound's therapeutic investigation appears to be a modern scientific endeavor.

Health Benefits

• May support cognitive function in mild cognitive impairment - based on ongoing T-COG trial (n=60) testing effects on Montreal Cognitive Assessment scores (evidence: preliminary, trial ongoing)
• Potential reduction in brain amyloid-beta deposition - one case report showed 22-24% reduction in Aβ deposition after 6-10 months (evidence: very preliminary, n=1)
• Exhibits anti-inflammatory and antioxidant properties - demonstrated in preclinical models only (evidence: preliminary, no human data)
• May protect against neuroinflammation - shown to inhibit hippocampal inflammation in experimental models (evidence: preliminary, animal studies only)
• Potential mitochondrial protective effects - observed in laboratory studies (evidence: preliminary, preclinical only)

How It Works

Taxifolin exerts its effects through multiple antioxidant pathways, including scavenging reactive oxygen species and chelating metal ions that promote oxidative stress. The compound modulates inflammatory mediators like NF-κB and cyclooxygenase enzymes while supporting mitochondrial function. In brain tissue, taxifolin may interfere with amyloid-beta protein aggregation and promote clearance of these neurotoxic plaques.

Scientific Research

The primary human evidence comes from the ongoing T-COG trial (PMID: 41158654), a randomized, double-blind, placebo-controlled crossover study testing 100mg daily taxifolin in 60 patients with mild cognitive impairment or mild dementia over 12 weeks. One case report (n=1) documented improvements in a 42-year-old man with cerebral amyloid angiopathy, showing 22-24% reductions in brain amyloid deposition. No completed human RCTs or meta-analyses are available.

Clinical Summary

Clinical evidence for taxifolin remains limited and preliminary. The ongoing T-COG trial (n=60) is investigating taxifolin's effects on cognitive function in mild cognitive impairment using Montreal Cognitive Assessment scores, but results are not yet available. One case report suggested a 22-24% reduction in brain amyloid-beta deposition, though single case studies provide weak evidence. Most research consists of preclinical studies in cell cultures and animal models rather than human trials.

Nutritional Profile

Taxifolin (flavanonol/dihydroquercetin) is a pure bioactive flavonoid compound, not a whole food, so it contains no macronutrients (protein, fat, carbohydrates), fiber, or caloric value in isolated supplemental form. Molecular weight: 304.25 g/mol. Chemical formula: C15H12O7. Bioactive compound concentration in supplements typically ranges from 90-99% purity (standardized extracts, commonly sourced from Siberian larch bark, Larix sibirica). In larch bark raw material, taxifolin content ranges approximately 70-90 mg/g dry weight. In grape seeds and skin, taxifolin occurs at lower concentrations (~0.1-1 mg/g). As a flavanonol, it contains a 3-hydroxyflavanone skeleton with five hydroxyl groups, contributing to its antioxidant activity (ORAC value estimated >6,000 µmol TE/g in isolated form). Bioavailability is considered moderate-to-low due to limited aqueous solubility (~0.5 mg/mL at room temperature); absorption occurs primarily in the small intestine with some colonic microbial metabolism producing phenolic acid metabolites (phloroglucinol, 3,4-dihydroxyphenylacetic acid). Lipid-based or nanoparticle formulations improve bioavailability by an estimated 2-4 fold. No significant vitamin or mineral content is inherent to the isolated compound.

Preparation & Dosage

The clinically studied dosage in the T-COG trial is 100 mg taxifolin capsules taken orally once daily for 12 weeks. No other dosage forms or ranges have been clinically tested. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified in research

Safety & Interactions

Taxifolin appears generally well-tolerated based on limited safety data, though comprehensive human safety studies are lacking. No significant drug interactions have been reported, but theoretical interactions may occur with anticoagulant medications due to potential effects on platelet function. Safety during pregnancy and breastfeeding has not been established. Individuals with bleeding disorders should exercise caution due to taxifolin's potential antiplatelet effects.